Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

Neil P. Shah, Francis Y. Lee, Roger Luo, Yibin Jiang, Marjolein Donker, Cem Akin

Open source

DOI
10.1182/blood-2005-10-3969
Published
2006-07-01
Container
Blood
Publisher
American Society of Hematology
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1182/blood-2005-10-3969,
  title = {Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis},
  author = {Neil P. Shah and Francis Y. Lee and Roger Luo and Yibin Jiang and Marjolein Donker and Cem Akin},
  year = {2006},
  journal = {Blood},
  doi = {10.1182/blood-2005-10-3969},
  url = {https://doi.org/10.1182/blood-2005-10-3969}
}

RIS

TY  - JOUR
TI  - Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
AU  - Neil P. Shah
AU  - Francis Y. Lee
AU  - Roger Luo
AU  - Yibin Jiang
AU  - Marjolein Donker
AU  - Cem Akin
PY  - 2006
JO  - Blood
DO  - 10.1182/blood-2005-10-3969
UR  - https://doi.org/10.1182/blood-2005-10-3969
ER  - 

APA

Shah, N. P., Lee, F. Y., Luo, R., Jiang, Y., Donker, M., & Akin, C. (2006). Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. https://doi.org/10.1182/blood-2005-10-3969

Source records